Merck is actually small potatoes in the larger patent war between the two pharma giants over a groundbreaking hepatitis C medicine. Merck obtained a $2.5 billion infringement judgment in Delaware against Gilead based on different patents. That verdict came down in December 2016, but U.S. District …
